Howlett, Sarah;
Carter, Thomas J;
Shaw, Heather M;
Nathan, Paul D;
(2023)
Tebentafusp: a first-in-class treatment for metastatic uveal melanoma.
Therapeutic Advances in Medical Oncology
, 15
10.1177/17588359231160140.
Preview |
Text
howlett-et-al-2023-tebentafusp-a-first-in-class-treatment-for-metastatic-uveal-melanoma.pdf - Published Version Download (616kB) | Preview |
Abstract
Tebentafusp is a first-in-class immunotherapy agent that comprises an engineered T-cell receptor targeting a gp100 epitope presented by human leukocyte antigen-A*02:01 cells, fused to an anti-CD3 single-chain variable fragment. Tebentafusp is both the first bispecific T-cell engager to show efficacy in the treatment of advanced solid cancer and the first anti-cancer treatment to demonstrate an overall survival benefit in patients with uveal melanoma (UM). This review article will focus on the clinical development of tebentafusp, the mechanism of action and resultant evolution of the management of advanced UM.
| Type: | Article |
|---|---|
| Title: | Tebentafusp: a first-in-class treatment for metastatic uveal melanoma |
| Location: | England |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1177/17588359231160140 |
| Publisher version: | https://doi.org/10.1177/17588359231160140 |
| Language: | English |
| Additional information: | © The Author(s), 2023. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
| Keywords: | Science & Technology, Life Sciences & Biomedicine, Oncology, gp100, ImmTAC, metastatic, tebentafusp, uveal melanoma, PHASE-II TRIAL, PD-L1 EXPRESSION, PATIENTS PTS, OPEN-LABEL, MULTICENTER, IPILIMUMAB, SURVIVAL, NIVOLUMAB, EFFICACY, GEMCITABINE |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Medicine UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute > Research Department of Oncology |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10176321 |
Archive Staff Only
 |
View Item |
